On June 4, 2026, the United States Supreme Court issued a unanimous opinion authored by Justice Jackson reversing the Federal Circuit and holding that Amarin Pharma failed to plausibly allege induced infringement under 35 U.S.C. § 271(b) against generic manufacturer Hikma Pharmaceuticals. The decision marks a significant development in the longstanding tension between branded pharmaceutical patent holders and generic manufacturers operating under the Hatch-Waxman framework, and it provides important clarity on the contours of the skinny-label pathway.
At the heart of the case was whether Hikma's combination of a skinny label carve-out, statements on its website, and press releases describing its product could support a claim that Hikma actively induced physicians and patients to infringe Amarin's patented method of use. The Court concluded that these materials, taken individually or together, did not amount to the affirmative conduct or active encouragement required to establish inducement liability. In doing so, the Court reinforced that mere awareness of potential infringing uses, or the publication of accurate descriptive materials about a generic product, is insufficient to satisfy the pleading standard under Section 271(b).
The ruling carries meaningful implications for both sides of the pharmaceutical industry. For generic manufacturers, the decision reaffirms the viability of the skinny-label pathway and signals that generics may market drugs for unpatented indications without triggering inducement liability, absent specific evidence of active encouragement to infringe a patented method. For branded patent holders, the decision raises the pleading bar considerably. Plaintiffs pursuing induced infringement claims will now need to identify concrete conduct demonstrating that a generic affirmatively encouraged use of its product for a patented indication, rather than relying on inference drawn from labeling, marketing materials, or general industry awareness.
Going forward, branded manufacturers should anticipate the need for more detailed factual development before filing suit, while generics should continue to ensure that their labeling and promotional communications remain carefully tailored to unpatented uses. Litigation strategy, regulatory positioning, and competitive intelligence efforts will all warrant recalibration in light of this decision.
This newsletter is for general informational purposes only. Clients facing pharmaceutical patent or Hatch-Waxman issues should seek tailored legal advice addressing their specific circumstances.